Pantogam, 10% syrup, 100ml

Composition

Active ingredient:

calcium hopanthenate – 10 g;

Auxiliary substances:

glycerol,

food grade sorbitol, food grade

citric acid, sodium benzoate,

aspartame,

aromatic food grade essence,

purified water

Pharmacological action

The spectrum of action of Pantogam® is associated with the presence of gamma-aminobutyric acid (GABA) in its structure. The mechanism of action is due to the direct effect of the drug on the GABAB-receptor-channel complex.

It has a nootropic and anticonvulsant effect. Increases the brain’s resistance to hypoxia and toxic substances, stimulates anabolic processes in neurons, combines a moderate sedative effect with a mild stimulating effect, reduces motor excitability, activates mental and physical performance.

Improves GABA metabolism during chronic alcohol intoxication and after ethanol withdrawal. It is able to inhibit acetylation reactions involved in the mechanisms of inactivation of procaine (novocaine) and sulfonamides, thereby prolonging the action of the latter. Causes inhibition of pathologically elevated cystic reflex and detrusor tone.

Pharmacokinetics

Pantogam® rapidly absorbed from the gastrointestinal tract, passes through the BBB, the highest concentrations are created in the liver, kidneys, stomach wall and skin. It is not metabolized and is excreted unchanged within 48 hours: 67.5% of the dose taken is excreted in the urine,28.5% – in the feces.

Indications

• cognitive disorders in organic brain lesions (including the consequences of neuroinfections and TBI) and neurotic disorders;
• schizophrenia with cerebral organic insufficiency;
• cerebrovascular insufficiency caused by atherosclerotic changes in vessels of the brain;
• extrapyramidal disorders (myoclonus epilepsy, Huntington’s chorea, hepatolenticular degeneration, Parkinson’s disease, etc. );
• treatment and prevention of extrapyramidal syndrome (hyperkinetic and akinetic) caused by neuroleptics;
• epilepsy with slowness of mental processes in complex therapy with anticonvulsants;
• psycho-emotional overload,
• reduced mental and physical performance, to improve concentration and memory;
• neurogenic disorders of urination (pollakiuria, urgency imperative, imperative urinary incontinence, enuresis).
• in children with perinatal encephalopathy;
• mental retardation of varying severity in children;
• developmental delay (mental, speech, motor or a combination of them) in children;
• various forms of cerebral palsy;
• hyperkinetic disorders (attention deficit hyperactivity disorder) in children;
• neurosis-like conditions (with stuttering, mainly in clonic form, tics) in children.

Contraindications

• hypersensitivity;
• acute severe kidney diseases;
• pregnancy (I trimester — syrup);
• pregnancy (tablets);
• phenylketonuria (syrup containing aspartame)
• breast-feeding period (tablets).
• children under 3 years of age (tablets).

Side effects

Allergic reactions:  rhinitis, conjunctivitis, and skin rashes are possible.

Other services:  possible sleep disturbances or drowsiness, tinnitus (these symptoms are usually short-lived and do not require discontinuation of the drug).

Interaction

Prolongs the action of barbiturates, enhances the effect of anticonvulsants, prevents side effects of phenobarbital, carbamazepine, neuroleptics.

Potentiates the action of local anesthetics (procaine).

The effect of Pantogam® is enhanced in combination with glycine, ethidronic acid (xydiphone).

How to take, course of use and dosage

Adults: single dose-2.5-10 ml (0.25-1 g), daily-15-30 ml (1.5-3 g); children: single dose — 2.5–5 ml (0.25–0.5 g), daily — 7.5–30 ml (0.75–3 g). The course of treatment is 1-4 months, sometimes up to 6 months. After 3-6 months, it is possible to conduct a second course of treatment.

Depending on the age and pathology of the nervous system, the following dose range is recommended for children: children of the first year-5-10 ml (0.5-1 g) per day, up to 3 years-5-12.5 ml (0.5-1.25 g) per day, children from 3 to 7 years — 7.5–15 ml (0.75–1.5 g), older than 7 years — 10-20 ml (1-2 g). The treatment strategy involves increasing the dose for 7-12 days, taking the maximum dose for 15-40 or more days with a gradual decrease in the dose until cancellation within 7-8 days. The course of treatment is 30-90 days (for some diseases up to 6 months or more).

For schizophrenia in combination with psychotropic drugs-from 5 to 30 ml (0.5-3 g) per day. The course of therapy is from 1 to 3 months.

For epilepsy in combination with anticonvulsants — at a dose of 7.5 to 10 ml (0.75-1 g) per day. The course of therapy is up to 1 year or more.

In neuroleptic syndrome accompanied by extrapyramidal disorders, the daily dose is up to 30 ml( up to 3 g), treatment for several months.

For extrapyramidal hyperkinesis in patients with organic diseases of the nervous system-from 5 to 30 ml (0.5-3 g) per day. The course of treatment is up to 4 months or more.

With the consequences of neuroinfections and TBI — from 5 to 30 ml (0.5-3 g) per day.

To restore performance under increased loads and asthenic conditions — 2.5-5 ml (0.25–0.5 g) 3 times a day.

For urination disorders, children — 2.5-5 ml (0.25-0.5 g), daily dose-25-50 mg / kg, course of treatment-1-3 months; adults-5-10 ml (0.5–1 g) 2-3 times a day.

In conditions of long-term treatment, simultaneous use of the drug with other nootropic and stimulating agents is not recommended. Taking into account the nootropic effect of the drug, its reception is carried out preferably in the morning and afternoon hours.

Overdose

Symptoms:  increased symptoms of side effects (sleep disturbance or drowsiness, noise in the head).

Treatment:  use of activated charcoal, gastric lavage, symptomatic therapy.

Special instructions

Information about the possible effect of the drug on the ability to drive vehicles and mechanisms.

In the first days of admission, care should be taken when driving vehicles and mechanisms, taking into account the possible occurrence of drowsiness.

Storage conditions

The drug should be stored in a place protected from light at a temperature of 15° to 20°C.

Shelf

life 1.5 years

Active ingredient

Hopanthenic acid

Conditions of release from pharmacies

By prescription

Dosage form

solution for oral use

Description

Children as prescribed by a doctor, Adults as prescribed by a doctor

Indications

Epilepsy, Low learning Ability, Atherosclerosis, Schizophrenia, Impaired cerebral circulation, Hyperactivity, Concussion and other traumatic brain injuries, Neurosis